San Diego news from FierceBiotech
News
Gen-Probe bids $334 for Innogenetics
In a bid to create the world's largest stand-alone molecular diagnostics company, San Diego-based Gen-Probe has launched a $334 million cash bid for Belgium's Innogenetics. That's a seven percent Read more...
Following trial failure, Favrille cuts staff
San Diego's Favrille is making massive cuts following the trial failure of Specifid announced earlier this week. The company is axing 132 of its 144 employees, including six of its eight executive Read more...
Favrille dumps Specifid after trial failure
San Diego-based Favrille has halted development of Specifid, a treatment for follicular B-cell non-Hodgkin's lymphoma. In a Phase III trial the drug failed to show a statistically significant Read more...
Forbes Medi-Tech gets out the axe, restructures
Forbes Medi-Tech says it will slash a third of its staff and shelve all in-house drug development work as it focuses its efforts on the nutraceutical business. The shakeup includes a move to shutter Read more...
California grants ignite a boom of lab construction
After four years of litigation and detailed planning, the first $271 million in facilities grants is just about ready to be doled out by the Read more...
San Diego institutes plan $115M stem cell lab
Four of San Diego's biggest research institutions are teaming up to form the San Diego Consortium for Regenerative Medicine, a group aimed at advancing stem cell work. The four research Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets